Written by: David Mandelbaum, Portfolio Manager

What Healthcare's Divergence Says About the Broader Equity Regime

Healthcare's underperformance is usually explained as a sector-specific problem: drug pricing pressure, managed care policy risk, biotech funding scarcity, post-COVID utilization normalization, and weak demand in life science tools. Those issues are real. But they are not the whole story. Healthcare has also become one of the clearest windows into what this equity market is willing to pay for, and what it is refusing to underwrite.

The important observation is not that healthcare is broken. It is that within healthcare, a narrow set of areas is working, including GLP-1 leaders with confirmed demand, managed care organizations with improving margin evidence, and select services or real-estate models where reimbursement, utilization, or contracted cash flows are highly visible. By contrast, much of biopharma, medical technology, life science tools, and diagnostics remains pinned near 52-week or even multi-year lows. What unifies the winners is not simply growth, defensiveness, or valuation. It is visible cash flow over the next twelve to twenty-four months. What unifies the laggards is the opposite: recovery that may be plausible, but is still more projected than proven.

That pattern fits naturally with a stagflationary market framework. When inflation risk is sticky and discount rates are less forgiving, equity markets compress the premium paid for projected recovery and expand the premium paid for confirmed earnings visibility. The market is not paying much for stories. It is paying for evidence.

The managed care reversal is the cleanest healthcare illustration. Eighteen months ago, the market increasingly treated MCOs as structurally impaired. Medicare Advantage rate pressure, V28 risk-adjustment changes, RADV audit expansion, and additional policy risk all appeared to be compounding into 2026 and 2027. In some cases, the group was priced as if margin stabilization itself was no longer underwritable. Then two things changed. The final Medicare Advantage rate landed at +2.48%, versus the proposed 0.09%, reducing the risk of another rate-driven margin reset. And a sequence of better earnings reports showed that pricing actions, benefit redesign, and cohort management were restoring margins faster than the bear case allowed. The subsequent re-rating was not about a new growth story. It was about the market becoming willing to pay for stabilization only after the evidence arrived.

That is the broader lesson. In the current regime, the market is not paying much for recovery that is merely expected. It is paying for recovery that is confirmed. Even in mega-cap technology, the market has favored companies that pair AI optionality with current cash flow, scale, and balance-sheet strength, while being less forgiving toward businesses where AI monetization remains distant, uncertain, or margin-dilutive. In industrials, companies with backlog visibility and funded demand have fared better than those waiting on a capex-cycle revival. Across sectors, the market is making a consistent choice: proof over promise.

A Three-Bucket Framework

The practical implication is a simple portfolio sorting discipline. Each position belongs in one of three categories.

The first category is confirmed-cash-flow positions. These are businesses where the earnings stream is visible, the market is already willing to pay for it, and the key question is whether the multiple already reflects too much certainty. GLP-1 leaders, some managed care names after the rate and earnings reset, healthcare REITs and others with contractual cash flows, and selected mega-cap technology leaders fit this profile.

The second category is pre-inflection positions. These are businesses where the operating data may be beginning to turn, but the market has not yet agreed to underwrite the recovery. This is often the most interesting opportunity set. The expected return is not driven simply by cheap valuation. It is driven by the possibility that one or two confirming data points move the stock from the projection bucket to the confirmation bucket.

The third category is projection-dependent positions. These are businesses where the investment case still requires the market to underwrite forward inference: a cycle that has not turned, market share that has not stabilized, a pipeline that has not read out, or margin recovery that has not appeared in the P&L. Many of these are high-quality businesses. The problem is not necessarily quality. The problem is catalyst visibility.

A portfolio that mixes these categories without distinguishing them is, in practice, a portfolio whose performance depends on regime persistence in ways that may not be transparent to the portfolio manager or the client. The clarifying question for every healthcare position, and for every position in the broader portfolio, is the same: is the market being asked to pay for the print or for the projection?

Why the Laggards Are Not All the Same

The healthcare laggards are useful because they fail the confirmation test in different ways. Each illustrates a distinct version of the projection problem, and each has a parallel outside healthcare.

Life science tools are the cleanest case of high-quality businesses pinned by unconfirmed end-market recovery. The leading life science tools companies have structural characteristics that should command premium multiples: recurring revenue, attractive margins, specialized customer relationships, and historically strong returns on capital. But the recovery thesis still depends on several things the market wants to see in the print: bioprocessing recovery, China stabilization, biopharma R&D spending normalization, and academic or government funding improvement. The market is not necessarily saying these businesses are impaired. It is saying it will not pay up until the inflection is visible.

The portfolio construction question for tools is therefore less whether the franchises remain high quality, and more whether the confirmation path is one quarter, four quarters, or eight. The catalysts to monitor are not macro variables in the abstract, but specific operating line items: bioprocessing book-to-bill, sequential China revenue stabilization, order trends, and R&D customer commentary on capital spending. The discipline is to size the positions for holding-period uncertainty, not merely for eventual upside.

The cross-sector parallel is industrial automation. High-quality franchises with structural growth narratives have repeatedly re-rated on hope and de-rated when the next quarter failed to confirm a capex turn. The market has learned to wait for the inflection rather than anticipate it, and that learned behavior is one of the defining features of the current regime.

Medical technology presents a different version of the same problem. In many cases, the end markets are not broken. Procedure volumes have been stable to growing. The issue is more often competitive, product-cycle-related, or execution-specific. Some franchises are facing share losses in specific product lines, operating leverage pressure, or uncertainty around whether new product cycles can offset legacy weakness. These are not necessarily “wait for the cycle” stories. They are “wait for execution” stories. The market is treating both with similar skepticism because both require evidence before the multiple can rebuild.

Broader biopharma illustrates the most extreme version of the projection problem: duration. Companies navigating patent cliffs, loss-of-exclusivity cycles, or pipeline-dependent reinvention are asking the market to pay today for cash flows that may be years away. In this regime, that duration is being priced punitively. The biopharma names that have worked best are those where current cash flow is visible and the pipeline is supplementary rather than central. The pattern is clear: the market is paying for what it can see and heavily discounting what it has to imagine.

This does not mean the laggards are bad businesses. It means their investment cases require something the market is currently unwilling to pay for in advance. That distinction matters. Business quality and catalyst visibility are not the same thing. In the current regime, the market is pricing them as if they are.

The Cross-Sector Read-Through

The same behavior is visible outside healthcare. In technology, the market has been willing to pay premium multiples for companies that combine AI optionality with current cash flow, scale, and clear demand signals. It has been less forgiving toward companies where the AI revenue path is credible but still distant, where monetization is unclear, or where spending is pressuring margins before revenue benefit is visible.

This dynamic can be seen most clearly in the latest leg of the semiconductor rally. When the market sees proof in the form of current demand, capex urgency, and earnings acceleration, it is willing to pay aggressively. But the same evidence that attracts capital can also create concentration, and that concentration can become a source of market fragility if the evidence begins to plateau.

In industrials, the dividing line is not simply cyclicality. Companies with backlog, funded programs, and order visibility have outperformed. Companies whose recovery depends on manufacturing capex, housing turnover, restocking, or commodity-price tailwinds have struggled when the expected inflection has not appeared in reported results.

In consumer staples, the group has bifurcated along similar lines. Companies with confirmed pricing power and stable volume have held up better than those whose thesis depends on volume recovery, margin repair, or input-cost relief that has not yet flowed through the P&L. A sector that should have been a broad beneficiary of a stagflationary regime has instead separated along visibility lines.

This is the regime's defining feature for equity strategy. It is not a clean quality-versus-junk regime, not a pure growth-versus-value regime, and not simply defensive-versus-cyclical. It is a confirmation-versus-projection regime. The market is applying a higher burden of proof to any cash flow that requires forward inference, and a much lower burden of proof to cash flow that is already visible in reported results.

Portfolio Implications

The implication is not to avoid all pre-inflection ideas. In fact, the best forward opportunities may sit precisely in businesses where the market is withholding valuation because confirmation has not yet arrived, but where the operating metrics suggest it may be close. The point is that valuation alone is not enough. Cheap quality can stay cheap if the catalyst remains diffuse, distant, or dependent on macro improvement.

The more useful discipline is to ask four questions about every position.

First, what specific data point would move the investment case from projection to confirmation? For tools, that may be bioprocessing orders or China stabilization. For MedTech, it may be segment-level share stabilization. For biopharma, it may be a clinical readout or evidence that a launch can offset a loss-of-exclusivity cliff. For industrials, it may be order growth or backlog conversion.

Second, how close is that confirming data point? A position whose confirmation can arrive on a known earnings date is different from a position that requires a broad macro cycle to turn over several quarters.

Third, how much is the market already paying for confirmation? Confirmed-cash-flow leaders may deserve premium valuations, but they are not riskless. Once the market is already paying for certainty, the risk shifts from “will the recovery arrive?” to “how much certainty is already in the multiple?”

Fourth, what is the appropriate sizing discipline? Confirmed positions can be larger if durability is real and valuation remains reasonable. Pre-inflection positions can be sized for asymmetry if the confirming catalyst is identifiable and proximate. Projection-dependent positions should be sized modestly unless the expected return compensates for time, uncertainty, and the possibility that the market continues to refuse to underwrite the thesis.

That sorting discipline is valuable because it makes the hidden bet in each position explicit. A portfolio can own confirmed cash flow, pre-inflection opportunity, and long-duration projection. But it should know which is which. Otherwise, the portfolio may appear diversified while actually depending on the same unspoken assumption: that the market will soon become more willing to pay for forward inference.

Conclusion

The healthcare tape is not telling us that healthcare is broken. It is telling us that the market is currently rewarding analytical precision about the gap between intrinsic business quality and the visibility of forward catalysts. That precision is portable beyond healthcare.

The opportunity is not simply to buy what is cheap, nor to crowd into what has already worked. It is to identify where the market is withholding valuation until proof arrives, where the proof may be close, and where the eventual transition from projection to confirmation can create positive expectancy.

In current conditions, that may be one of the most important disciplines in equity strategy. The market is paying for proof, not promise. The task is to know which one each position is asking investors to buy.

If you’d like to discuss how a more selective, evidence-driven approach may fit within your broader portfolio, we invite a confidential conversation with our investment team.

Disclaimers

David Mandelbaum is solely an investment advisor representative and a lead portfolio manager of OnePoint BFG Wealth Partners, a registered investment adviser. Investment advisory and financial planning services offered through Bleakley Financial Group LLC, an SEC registered investment adviser, doing business as OnePoint BFG Wealth Partners. 

The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. The market and economic data is historical and is no guarantee of future results. All indices are unmanaged and may not be invested into directly. The information in this report has been prepared from data believed to be reliable, but no representation is being made as to its accuracy and completeness.

Nothing in this material should be construed as investment advice offered by OnePoint BFG Wealth Partners or David Mandelbaum. This market commentary is for informational purposes only and is not meant to constitute a recommendation of any particular investment, security, portfolio of securities, transaction or investment strategy. No chart, graph, or other figure provided should be used to determine which securities to buy, sell, or hold. No representation is made concerning the appropriateness of any particular investment, security, portfolio of securities, transaction or investment strategy. You should speak with your own financial professional before making any investment decisions.

Past performance is not indicative of future results. Neither OnePoint BFG Wealth Partners nor David Mandelbaum guarantees any specific outcome or profit. These disclosures cannot and do not list every conceivable factor that may affect the results of any investment or investment strategy. Risks will arise, and an investor must be willing and able to accept those risks, including the loss of principal.

Certain statements contained herein are statements of future expectations and other forward-looking statements that are based on opinions and assumptions that involve known and unknown risks and uncertainties that would cause actual results, performance or events to differ materially from those expressed or implied in such statements.

 OP 26-4006